First-in-Human Safety, Tolerability, and Pharmacokinetics of Single-Dose Kukoamine B Mesylate in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase I Study

被引：0
|
作者：
Hongzhong Liu
Qian Zhao
Yuping Yuan
Zhenlei Wang
Teng Wang
Wei Tian
Wen Zhong
Ji Jiang
Shuai Chen
Kai Kong
Chunyan Jin
Pei Hu
机构：
[1] Peking Union Medical College Hospital,Clinical Pharmacology Research Center, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK and PD Investigat
[2] Chinese Academy of Medical Sciences & Peking Union Medical College,Clinical Research Center for Innovative Drugs
[3] Tianjin Chasesun Pharmaceutical Co.,undefined
[4] Ltd.,undefined
来源：
Infectious Diseases and Therapy | 2024年 / 13卷
关键词：
Kukoamine B; Phase I trial; Pharmacokinetic; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：361 / 371
页数：10
相关论文
共 50 条
  • [1] First-in-Human Safety, Tolerability, and Pharmacokinetics of Single-Dose Kukoamine B Mesylate in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase I Study
    Liu, Hongzhong
    Zhao, Qian
    Yuan, Yuping
    Wang, Zhenlei
    Wang, Teng
    Tian, Wei
    Zhong, Wen
    Jiang, Ji
    Chen, Shuai
    Kong, Kai
    Jin, Chunyan
    Hu, Pei
    INFECTIOUS DISEASES AND THERAPY, 2024, 13 (02) : 361 - 371
  • [2] First-in-human safety, tolerability, and pharmacokinetics of ammoxetine in healthy subjects: a randomized, double-blind, placebo-controlled phase I study
    Shen, Qi
    Hu, Chao
    Miao, Jia
    Chen, Junxia
    Peng, Yueying
    Pan, Tingting
    He, Xiaolin
    Yuan, Jing
    Ni, Shaonan
    Wang, Yongsheng
    Luo, Zhu
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 159
  • [3] Safety, Tolerability, and Pharmacokinetics of Kukoamine B in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase I Study
    Qian Zhao
    Hongzhong Liu
    Zhenlei Wang
    Teng Wang
    Cheng Cui
    Huanhuan Wang
    Lili Li
    Wen Zhong
    Ji Jiang
    Kai Dong
    Shuai Chen
    Chunyan Jin
    Pei Hu
    Advances in Therapy, 2023, 40 : 3186 - 3198
  • [4] Safety, Tolerability, and Pharmacokinetics of Kukoamine B in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase I Study
    Zhao, Qian
    Liu, Hongzhong
    Wang, Zhenlei
    Wang, Teng
    Cui, Cheng
    Wang, Huanhuan
    Li, Lili
    Zhong, Wen
    Jiang, Ji
    Dong, Kai
    Chen, Shuai
    Jin, Chunyan
    Hu, Pei
    ADVANCES IN THERAPY, 2023, 40 (07) : 3186 - 3198
  • [5] Safety, tolerability, and pharmacokinetics of JX11502MA in Chinese healthy subjects: a first-in-human, randomized, double-blind, placebo-controlled study following single-dose administration
    Yu, Yimin
    He, Jingjing
    Huang, Zhiwei
    Li, Yan
    Wu, Ying
    Shen, Yifeng
    Zhou, Yanling
    Bao, Cungang
    Jin, Zhiping
    Li, Huafang
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024, 33 (01) : 51 - 61
  • [6] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study
    Haiyan Li
    Yudong Wei
    Zhenhua Yang
    Shuang Zhang
    Xiuxiu Xu
    Mengmeng Shuai
    Olivier Vitse
    Yiwen Wu
    Marie T. Baccara-Dinet
    Yi Zhang
    Jianyong Li
    American Journal of Cardiovascular Drugs, 2020, 20 : 489 - 503
  • [7] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study
    Li, Haiyan
    Wei, Yudong
    Yang, Zhenhua
    Zhang, Shuang
    Xu, Xiuxiu
    Shuai, Mengmeng
    Vitse, Olivier
    Wu, Yiwen
    Baccara-Dinet, Marie T.
    Zhang, Yi
    Li, Jianyong
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2020, 20 (05) : 489 - 503
  • [8] A Phase I, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects
    Liu, Chao
    Lu, Hong
    Yuan, Fei
    Chen, Wei-Li
    Xu, Hong-Rong
    Li, Hui
    Hsu, Cheng-Pang
    Egbuna, Ogo
    Wu, Jihua
    Dias, Clapton
    Abosaleem, Bassam
    Rana, Jitesh
    Monsalvo, Maria Laura
    Li, Xue-Ning
    Yu, Zhigang
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2019, 11 : 145 - 153
  • [9] Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Volunteers: a Randomized, Placebo-Controlled First-in-Human Single-Dose Escalation Study
    An, Guohua
    Murry, Daryl J.
    Gajurel, Kiran
    Bach, Thanh
    Deye, Greg
    Stebounova, Larissa, V
    Codd, Ellen E.
    Horton, John
    Gonzalez, Armando E.
    Garcia, Hector H.
    Ince, Dilek
    Hodgson-Zingman, Denice
    Nomicos, Effie Y. H.
    Conrad, Thomas
    Kennedy, Jessie
    Jones, Walt
    Gilma, Robert H.
    Winokur, Patricia
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (04)
  • [10] Safety, tolerability, and pharmacokinetic of HY0721 in Chinese healthy subjects: A first-in-human randomized, double-blind, placebo-controlled dose escalation phase I study
    Zhang, Mengyu
    Liu, Runhan
    Wang, Ying
    Zhu, Xiaohong
    Wang, Zhenlei
    Li, Xiaoyu
    Zheng, Li
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 200
12345